ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur CINQAERO® solution à diluer pour perfusion:Teva Pharma AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
R03DX08 - ReslizumabATC-DDD Version 2016. Source: WHO
R - Respiratory System

Inhaled antiinfectives are classified in ATC group J - Antiinfectives for systemic use.

R03 - Drugs for Obstructive Airway Diseases
 
R03D - Other Systemic Drugs for Obstructive Airway Diseases

Theophyllines are classified in this group. Other respiratory stimulants are classified in R07AB - Respiratory stimulants.
Corticosteroids for systemic use, see H02.
Sympathomimetics for systemic treatment of rhinitis, see R01BA.

This group comprises mainly the xanthines. The DDDs for these substances are based on treatment of obstructive lung diseases.

R03DX - Other Systemic Drugs for Obstructive Airway Diseases

This group comprises preparations, which cannot be classified in the preceding groups.
Interleukin inhibitors used in asthma are classified in this group.

R03DX08 - Reslizumab
Concentr.Adm.RouteNote
 P 
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home